PMID- 2903446
OWN - NLM
STAT- MEDLINE
DCOM- 19881205
LR  - 20211203
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 319
IP  - 19
DP  - 1988 Nov 10
TI  - Neu-protein overexpression in breast cancer. Association with comedo-type ductal 
      carcinoma in situ and limited prognostic value in stage II breast cancer.
PG  - 1239-45
AB  - Amplification of the neu proto-oncogene in breast cancer has been reported to 
      correlate with the presence of lymph-node metastases and with a poor prognosis. 
      We describe a method for the immunohistochemical detection of overexpression of 
      neu protein on formalin-fixed paraffin-embedded tissue, with the use of two 
      different monoclonal antibodies. In a group of tumors with a known neu-gene copy 
      number, intense membrane staining of tumor cells was present in all tumors with 
      neu-gene amplification. Of 189 tumors from patients with Stage II breast cancer, 
      27 (14 percent) had neu-membrane staining. Neu overexpression was associated with 
      larger tumor size (P = 0.006) but not with lymph-node involvement. Neu-protein 
      expression in lymph-node metastases was the same as its expression in primary 
      tumors. Among the patients with neu overexpression (median follow-up, 37 months), 
      disease-free survival was not significantly shorter; overall survival was reduced 
      significantly in these patients (P = 0.042), but this reduction did not remain 
      significant after adjustment for tumor size. Of 45 ductal carcinomas in situ, 19 
      (42 percent) had neu-membrane staining. These 19 were all of the large-cell, 
      comedo growth type. None of 16 ductal carcinomas in situ of small-cell, 
      papillary, or cribriform growth type had neu overexpression. We conclude that neu 
      overexpression may be an early step in the development of a distinct histologic 
      type of carcinoma of the breast, but we could find no association of 
      overexpression with lymph-node status or tumor recurrence.
FAU - van de Vijver, M J
AU  - van de Vijver MJ
AD  - Department of Pathology, Netherlands Cancer Institute, Amsterdam.
FAU - Peterse, J L
AU  - Peterse JL
FAU - Mooi, W J
AU  - Mooi WJ
FAU - Wisman, P
AU  - Wisman P
FAU - Lomans, J
AU  - Lomans J
FAU - Dalesio, O
AU  - Dalesio O
FAU - Nusse, R
AU  - Nusse R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MAS1 protein, human)
RN  - 0 (Proto-Oncogene Mas)
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Antibodies, Monoclonal
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/*diagnosis/genetics/pathology
MH  - Carcinoma in Situ/*diagnosis/genetics/pathology
MH  - Carcinoma, Intraductal, Noninfiltrating/*diagnosis/genetics/pathology
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Lymph Nodes/pathology
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Precipitin Tests
MH  - Prognosis
MH  - Proto-Oncogene Mas
MH  - Proto-Oncogene Proteins/*analysis
MH  - *Proto-Oncogenes
MH  - Receptor, ErbB-2
MH  - Transfection
EDAT- 1988/11/10 00:00
MHDA- 1988/11/10 00:01
CRDT- 1988/11/10 00:00
PHST- 1988/11/10 00:00 [pubmed]
PHST- 1988/11/10 00:01 [medline]
PHST- 1988/11/10 00:00 [entrez]
AID - 10.1056/NEJM198811103191902 [doi]
PST - ppublish
SO  - N Engl J Med. 1988 Nov 10;319(19):1239-45. doi: 10.1056/NEJM198811103191902.